M&A Deal Summary

Cambrex Acquires Avista Pharma Solutions

On November 20, 2018, Cambrex acquired life science company Avista Pharma Solutions from Ampersand Capital Partners for 252M USD

Acquisition Highlights
  • This is Cambrex’s 4th transaction in the Life Science sector.
  • This is Cambrex’s 2nd largest (disclosed) transaction.
  • This is Cambrex’s 3rd transaction in the United States.
  • This is Cambrex’s 1st transaction in Colorado.

M&A Deal Summary
Date 2018-11-20
Target Avista Pharma Solutions
Sector Life Science
Buyer(s) Cambrex
Sellers(s) Ampersand Capital Partners
Deal Type Add-on Acquisition
Deal Value 252M USD
Advisor(s) Goodwin Procter (Legal)

Target

Avista Pharma Solutions

Lafayette, Colorado, United States
Avista Pharma Solutions is a contract development, manufacturing, and testing organization that understands advance products through every stage of development. With over 200,000 square feet of laboratory and manufacturing space in the U.S. and U.K., Avista offers a broad suite of scientifically differentiated services ranging from early-stage discovery, API and Drug Product development and cGMP manufacturing to stand-alone analytical and microbiology testing support.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Cambrex

East Rutherford, New Jersey, United States
Category Company
Founded 1981
Sector Life Science
Employees1,228
Revenue 534M USD (2017)
DESCRIPTION

Cambrex is a life sciences company that provides products, services, and technologies to accelerate the development and commercialization of small molecule therapeutics. Cambrex was formed in 1981 and is headquartered in East Rutherford, New Jersey.

DEAL STATS #
Overall 5 of 7
Sector (Life Science) 4 of 5
Type (Add-on Acquisition) 4 of 6
State (Colorado) 1 of 1
Country (United States) 3 of 4
Year (2018) 2 of 2
Size (of disclosed) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-07-23 Cambrex Drug Product- Business Unit

Whippany, New Jersey, United States

Cambrex Drug Product's Business Unit is a technology-focused contract manufacturing business with differentiated applications and capabilities in solid, semi-solid and liquid dosage forms, with a particular focus on controlled substances. Cambrex Drug Product's Business Unit was established in 2006 and is based in Whippany, New Jersey.

Buy $425M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-06-01 Q1 Scientific

Waterford, Ireland

Q1 Scientific is a provider of environmentally-controlled cGMP stability storage services for the pharmaceutical, medical device, and life science industries. Q1 Scientific was founded in 2013 and is based in Waterford, Ireland.

Buy -

Seller(S) 1

SELLER

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1988
PE ASSETS 2.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 39 of 55
Sector (Life Science) 16 of 25
Type (Add-on Acquisition) 28 of 38
State (Colorado) 1 of 1
Country (United States) 39 of 51
Year (2018) 6 of 6
Size (of disclosed) 7 of 13
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-10-23 Genoptix

Carlsbad, California, United States

Genoptix, Inc. is one of the largest hematopathology testing laboratories in the U.S., providing thousands of oncologists and pathologists across the United States with comprehensive testing solutions in hematology and solid tumor molecular profiling. Genoptix, Inc. was founded in 1999 and is based in Carlsbad, California.

Sell $126M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-03-24 Brammer Bio

Cambridge, Massachusetts, United States

Brammer Biopharmaceuticals LLC was founded early in 2015 to create a best-in-class cell and gene therapy contract development and manufacturing organization (CDMO) to enable large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health. With the in-depth biologics manufacturing knowledge and expertise of founders Mark Bamforth (CEO) and Steven Kasok (CFO), previously cofounders of Gallus Biopharmaceuticals, now as Brammer Bio, the company is positioned to accelerate the development of these important emerging technologies.

Sell $1.7B
Mergr

Product

Company

Legal